Transplantation programs facing lack of empirical evidence on SARS-CoV-2 vaccination: A society recommendation consensus update.
COVID-19
SARS-CoV-2 vaccination
solid organ transplantation
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
30
06
2021
received:
23
06
2021
accepted:
05
07
2021
pubmed:
22
7
2021
medline:
23
9
2021
entrez:
21
7
2021
Statut:
ppublish
Résumé
Since phase III trials for the most prominent vaccines excluded immunocompromised or immunosuppressed patients, data on safety and efficacy of SARS-CoV-2 vaccines for recipients of solid organ transplantations are scarce. Our study offers a synthesis of expert opinions aligned with available data addressing key questions of the clinical management of SARS-CoV-2 vaccinations for transplant patients. An online research was performed retrieving available recommendations by national and international transplantation organizations and state institutions on SARS-CoV2 vaccination management for transplant recipients. Eleven key statements were identified from recommendations by 18 national and international societies, and consensus for the individual statements was evaluated by means of the Society Recommendation Consensus score. The highest consensus level (SRC A) was found for prioritized access to vaccination for transplant patients despite anticipation of a weakened immune response. All currently authorized vaccines can be considered safe for transplant patients (SRC A). The handling of immunosuppressive medication, the timely management of vaccines, and other aspects were aligned with available expert opinions. Expert consensus can be determined for crucial aspects of the implementation of SARS-CoV-2 vaccination programs. We hereby offer a tool for immediate decision-making until empirical data becomes available.
Sections du résumé
BACKGROUND
BACKGROUND
Since phase III trials for the most prominent vaccines excluded immunocompromised or immunosuppressed patients, data on safety and efficacy of SARS-CoV-2 vaccines for recipients of solid organ transplantations are scarce.
AIMS
OBJECTIVE
Our study offers a synthesis of expert opinions aligned with available data addressing key questions of the clinical management of SARS-CoV-2 vaccinations for transplant patients.
METHOD
METHODS
An online research was performed retrieving available recommendations by national and international transplantation organizations and state institutions on SARS-CoV2 vaccination management for transplant recipients.
RESULTS
RESULTS
Eleven key statements were identified from recommendations by 18 national and international societies, and consensus for the individual statements was evaluated by means of the Society Recommendation Consensus score. The highest consensus level (SRC A) was found for prioritized access to vaccination for transplant patients despite anticipation of a weakened immune response. All currently authorized vaccines can be considered safe for transplant patients (SRC A). The handling of immunosuppressive medication, the timely management of vaccines, and other aspects were aligned with available expert opinions.
CONCLUSION
CONCLUSIONS
Expert consensus can be determined for crucial aspects of the implementation of SARS-CoV-2 vaccination programs. We hereby offer a tool for immediate decision-making until empirical data becomes available.
Identifiants
pubmed: 34288294
doi: 10.1111/tid.13696
pmc: PMC8420432
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13696Informations de copyright
© 2021 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Ann Intern Med. 2020 Dec 15;173(12):964-973
pubmed: 32886525
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Clin Ther. 2017 Aug;39(8):1581-1598
pubmed: 28751095
J Heart Lung Transplant. 2021 Mar;40(3):169-171
pubmed: 33487534
Pediatr Transplant. 2019 Nov;23(7):e13571
pubmed: 31497926
BMJ Open. 2019 Sep 6;9(9):e031070
pubmed: 31494620
Am J Transplant. 2020 Nov;20(11):3008-3018
pubmed: 32780493
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Clin Transplant. 2019 Sep;33(9):e13563
pubmed: 31002409
Am J Transplant. 2021 Aug;21(8):2913-2915
pubmed: 33864722
Transplantation. 2021 Jan 1;105(1):37-55
pubmed: 33148977
Kidney Int. 2012 Jul;82(2):212-9
pubmed: 22495292
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):156-158
pubmed: 33444545
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
Am J Transplant. 2020 Jul;20(7):1826-1836
pubmed: 32323460
BMJ Open. 2016 Jan 28;6(1):e009264
pubmed: 26823177
Transpl Infect Dis. 2021 Aug;23(4):e13696
pubmed: 34288294
Transpl Int. 2021 Oct;34(10):1770-1775
pubmed: 34288160
Kidney Int. 2021 Jun;99(6):1487-1489
pubmed: 33775674
Kidney Int. 2020 Dec;98(6):1549-1558
pubmed: 32853631
Transplantation. 2021 May 1;105(5):e56-e57
pubmed: 33560728
JAMA. 2021 May 4;325(17):1784-1786
pubmed: 33720292
N Engl J Med. 2021 May 6;384(18):1774-1775
pubmed: 33755376